Increased priority for regimens involving incretin-based and insulin therapy

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Current diabetes guidelines emphasize personalized treatment approaches.
• Metformin is the established first-line therapy for most patients with type 2 diabetes.
• Incretin-based therapies have gained prominence in treatment algorithms.

Purpose of the Study:

• To review the current guidelines and algorithms for type 2 diabetes management.
• To highlight the roles of incretin-based therapies and insulin in treatment strategies.
• To discuss the benefits of specific agents for glycemic control, hypoglycemia risk, and weight management.

Main Methods:

• Review of ADA/EASD and AACE guidelines and algorithms.
• Analysis of the positioning of incretin-based therapies (GLP-1R agonists, DPP-4 inhibitors) and insulin.
• Evaluation of therapeutic considerations based on HbA1c levels, glucotoxicity, and patient-specific goals.

Main Results:

• Metformin remains the preferred initial therapy.
• Incretin-based therapies and insulin are prioritized for consideration.
• GLP-1R agonists are beneficial for reducing hypoglycemia and promoting weight loss.
• Insulin is indicated for high HbA1c levels, glucotoxicity, or treatment failure.
• Combination therapy with GLP-1R agonists and basal insulin offers improved glycemic control with less weight gain and hypoglycemia.

Conclusions:

• Individualized treatment selection is crucial in diabetes care.
• Incretin-based therapies and insulin are vital components of modern diabetes management.
• Combination therapy with GLP-1R agonists and basal insulin presents a favorable risk-benefit profile.